Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring Nov 08, 2018 7:00am EST
Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting Oct 12, 2018 4:01pm EDT
Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe Acute Pain Oct 11, 2018 7:00am EDT
Trevena announces completion of leadership transition and appointment of new director Oct 01, 2018 7:00am EDT
Trevena to Present Oliceridine, a Next Generation IV Opioid for the Management of Moderate to Severe Acute Pain, at FDA Advisory Committee Meeting on October 11, 2018 Sep 10, 2018 4:01pm EDT
Trevena to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Aug 30, 2018 4:30pm EDT
Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine Jun 28, 2018 4:01pm EDT
